An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma

Table 5

Comparison between the two groups regarding the first location of tumor recurrences.

Metastasis site	Group I (no. and %)	Group II (no. and %)	P values
Intrahepatic	35 (42.7%)	31 (33.1%)	.ns
Locoregional	14 (17.1%)	29 (30.8%)	0.032
Peritoneal	12 (14.8%)	11 (11.7%)	.ns
Pulmonary	10 (12.2%)	12 (12.9%)	.ns
Retroperitoneal	7 (8.5%)	6 (6.4%)	.ns
Others	4 (4.9%)	5 (5.3%)	.ns